Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | FGR | P09769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13468048 | 0.89 | ADORA2A (0.59) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL308115 | 0.87 | ADORA2A (0.76) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30886455 | 0.87 | ALDH1A1 (0.67) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL55743 | 0.87 | ALDH1A1 (0.67) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| Dichlon SCHEMBL9820419 | 0.86 | IDO1 (0.67) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL9267831 | 0.83 | ALDH1A1 (0.62) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28115066 | 0.82 | NSD2 (0.49) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16281847 | 0.81 | ALDH1A1 (0.66) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5109323 | 0.80 | ADORA2A (1.00) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3581453 | 0.78 | CYP1A1 (1.00) | ADORA2ACYP1A1CYP1A2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | disclosed |
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | disclosed |
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | disclosed |
| EP-2697205-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | disclosed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | disclosed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141604-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | INSTYTUT FARMACEUTYCZNY (PL) | 2012-10-18 | — | — | WO | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20020032256-A1 | Polybutadiene composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0432095-A1 | Anthraquino vat dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| EP-0274458-B1 | ANTHRAQUINONE VAT DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1990-09-19 | — | — | EP | disclosed |
| EP-0274356-B1 | VATTABLE 2-ARYL-4,6-DIAMINOPYRIMIDINE | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| US-4845220-A | Vattable 2-aryl-4,6-diaminopyrimidines | CIBA-GEIGY CORPORATION | 1989-07-04 | — | — | US | disclosed |
| EP-0274356-A1 | Vattable 2-aryl-4,6-diaminopyrimidine | CIBA-GEIGY AG (CH) | 1988-07-13 | — | — | EP | disclosed |
| EP-0274458-A1 | Anthraquinone vat dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1988-07-13 | — | — | EP | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
| US-3972881-A | VAT, CELLULOSE | CIBA-GEIGY CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
| US-3935208-A | NATURAL OR REGENERATED CELLULOSE | ALTERMATT HANS | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | ABCC1, ABCC3, ABCB1 | ADORA2A 665/4885CYP1A1 866/4885CYP1A2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.